{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:10:09Z","timestamp":1745431809548,"version":"3.40.4"},"reference-count":23,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background: &lt;\/i&gt;&lt;\/b&gt;In this study, we aimed to evaluate the clinicopathological characteristics and prognosis of patients with primary peritoneal carcinoma (PPC), and the effectiveness and toxicity of first-line platinum\/taxane combination therapy. &lt;b&gt;&lt;i&gt;Patients and Methods: &lt;\/i&gt;&lt;\/b&gt;We retrospectively evaluated 79 patients with PPC, who were treated and followed up between December 2001 and August 2012 at 10 medical oncology clinics. &lt;b&gt;&lt;i&gt;Results: &lt;\/i&gt;&lt;\/b&gt;All patients were female, with a median age of 63 years (range 34-79 years). Histopathological diagnoses included primary peritoneal serous carcinoma (PPSC) (n = 69) and mixed epithelial carcinoma of the peritoneum (MEC) (n = 10). Patients received first-line treatment with carboplatin\/paclitaxel (n = 67) or cisplatin\/paclitaxel (n = 12) combination therapy. Overall response rate, median progression-free survival, and median survival time in the paclitaxel\/carboplatin group and the paclitaxel\/cisplatin group were 74.6 vs. 75%, 15.6 vs. 37.8 months, and 41 vs. 70.3 months, respectively. In multivariate analysis, favorable prognostic factors were: ECOG performance status 0 (p &lt; 0.001) and optimal cytoreduction (p = 0.03). &lt;b&gt;&lt;i&gt;Conclusion: &lt;\/i&gt;&lt;\/b&gt;PPC is a rare, heterogeneous disease. ECOG performance status and optimal cytoreduction are important prognostic factors regarding survival rates. Platinum\/taxane combination therapy is an effective and tolerable regimen in this patient group.<\/jats:p>","DOI":"10.1159\/000362857","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T10:24:53Z","timestamp":1401877493000},"page":"332-338","source":"Crossref","is-referenced-by-count":6,"title":["Treatment and Prognostic Factors in Primary Peritoneal Carcinoma: A Multicenter Study of the Anatolian Society of Medical Oncology (ASMO)"],"prefix":"10.1159","volume":"37","author":[{"given":"Olcun U.","family":"Unal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lhan","family":"Oztop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahsin","family":"Ozatli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"\u0130nal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"G\u00fcnayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Alici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Havva Y.","family":"Cinkir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilge","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kubra","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogan","family":"Uncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet U.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berna","family":"Oksuzoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suleyman","family":"Buyukberber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00650-9"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B0820051"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2003.13605.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6176"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6853"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2001.01027.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00590.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1223"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00314.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2003.09.073"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1267"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000351256"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5090"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4843"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0060"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198811000-00003"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5159"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.02.020"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0466-z"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61157-0"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00712.x"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/362857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/362857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:43:19Z","timestamp":1745430199000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000362857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000362857","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"type":"print","value":"2296-5270"},{"type":"electronic","value":"2296-5262"}],"subject":[],"published":{"date-parts":[[2014]]}}}